Skip to main content
Top
Published in: Journal of General Internal Medicine 9/2010

Open Access 01-09-2010 | Original Research

The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment

Authors: James E. Egan, MPH, Paul Casadonte, MD, Tracy Gartenmann, Judith Martin, MD, Elinore F. McCance-Katz, MD, PhD, Julie Netherland, MSW, John A. Renner, MD, Linda Weiss, PhD, Andrew J. Saxon, MD, David A. Fiellin, MD

Published in: Journal of General Internal Medicine | Issue 9/2010

Login to get access

ABSTRACT

Opioid dependence is largely an undertreated medical condition in the United States. The introduction of buprenorphine has created the potential to expand access to and use of opioid agonist treatment in generalist settings. Physicians, however, often have limited training and experience providing this type of care. Some physicians believe having a mentoring relationship with an experienced provider during their initial introduction to the use of buprenorphine would ease implementation. Our goal was to describe the development, implementation, resources, and evaluation of the Physician Clinical Support System-Buprenorphine (PCSS-B), a federally funded program to improve access to and quality of treatment with buprenorphine. We provide a description of the PCSS-B, a national network of 88 trained physician mentors with expertise in buprenorphine treatment and skills in clinical education. We provide information regarding the use the PCSS-B core services including telephone, email and in-person support, a website, clinical guidances, a warmline and outreach to primary care and specialty organizations. Between July 2005 and July 2009, 67 mentors and 4 clinical experts reported providing mentoring services to 632 participants in 48 states, Washington DC and Puerto Rico. A total of 1,455 contacts were provided through email (45%), telephone (34%) and in-person visits (20%). Seventy-six percent of contacts addressed a clinical issue. Eighteen percent of contacts addressed a logistical issue. The number of contacts per participant ranged from 1–125. Between August 2005 and April 2009 there were 72,822 visits to the PCSS-B website with 179,678 pages viewed. Seven guidances were downloaded more than 1000 times. The warmline averaged more than 100 calls per month. The PCSS-B model provides support for a mentorship program to assist non-specialty physicians in the provision of buprenorphine and may serve as a model for dissemination of other types of care.
Literature
1.
go back to reference Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 national survey on drug use and health. Rockville: Substance Abuse and Mental Health Services Administration; 2004. Substance Abuse and Mental Health Services Administration. Overview of findings from the 2003 national survey on drug use and health. Rockville: Substance Abuse and Mental Health Services Administration; 2004.
2.
go back to reference Substance Abuse and Mental Health Services Administration. National household survey on drug abuse. Substance Abuse and Mental Health Services Administration; 2006. Substance Abuse and Mental Health Services Administration. National household survey on drug abuse. Substance Abuse and Mental Health Services Administration; 2006.
3.
go back to reference Substance Abuse and Mental Health Services Administration. Overview of findings from the 2007 national survey on drug use and health. Rockville: Substance Abuse and Mental Health Services Administration; 2008. Substance Abuse and Mental Health Services Administration. Overview of findings from the 2007 national survey on drug use and health. Rockville: Substance Abuse and Mental Health Services Administration; 2008.
4.
go back to reference Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan TA, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153–9.CrossRefPubMed Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan TA, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153–9.CrossRefPubMed
5.
go back to reference Laine C, Hauck WW, Gourevitch MN, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285(18):2355–62.CrossRefPubMed Laine C, Hauck WW, Gourevitch MN, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285(18):2355–62.CrossRefPubMed
6.
go back to reference O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000;133(1):40–54.PubMed O’Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000;133(1):40–54.PubMed
7.
go back to reference Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327–33.PubMed Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the “narc” cabinet. J Gen Intern Med. 2002;17(5):327–33.PubMed
8.
go back to reference Fiellin DA, O’Connor PG, Chawarski M, Schottenfeld RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict. 2004;13(Suppl 1):67–78.CrossRef Fiellin DA, O’Connor PG, Chawarski M, Schottenfeld RS. Processes of care during a randomized trial of office-based treatment of opioid dependence in primary care. Am J Addict. 2004;13(Suppl 1):67–78.CrossRef
9.
go back to reference Fiellin DA, O’Connor P. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137(8):688–92.PubMed Fiellin DA, O’Connor P. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002;137(8):688–92.PubMed
10.
go back to reference Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust. 2003;179(1):38–42.PubMed Gibson AE, Doran CM, Bell JR, Ryan A, Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: a randomised trial. Med J Aust. 2003;179(1):38–42.PubMed
11.
go back to reference Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians’ offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9(3):127–30.CrossRefPubMed Novick DM, Joseph H, Salsitz EA, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians’ offices (medical maintenance): follow-up at three and a half to nine and a fourth years. J Gen Intern Med. 1994;9(3):127–30.CrossRefPubMed
12.
go back to reference O’Connor PG, Samet JH. The substance-using human immunodeficiency virus patient: approaches to outpatient management. Am J Med. 1996;101(4):435–44.CrossRefPubMed O’Connor PG, Samet JH. The substance-using human immunodeficiency virus patient: approaches to outpatient management. Am J Med. 1996;101(4):435–44.CrossRefPubMed
13.
go back to reference O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100–5.CrossRefPubMed O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105(2):100–5.CrossRefPubMed
14.
go back to reference National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. JAMA. 1998;280(1936–1943). National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. JAMA. 1998;280(1936–1943).
15.
go back to reference National Poll of Physicians Finds Barriers to Widespread Buprenorphine Use. Boston, MA: Join Together, Boston University School of Public Health; 2003. National Poll of Physicians Finds Barriers to Widespread Buprenorphine Use. Boston, MA: Join Together, Boston University School of Public Health; 2003.
16.
go back to reference Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2006;164–74. Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2006;164–74.
17.
go back to reference Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30(4):363–73.CrossRefPubMed Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30(4):363–73.CrossRefPubMed
19.
go back to reference Renner J. Education status report: successes & challenges. Personal communication 2-21-2008 (slide set). Renner J. Education status report: successes & challenges. Personal communication 2-21-2008 (slide set).
20.
go back to reference Substance Abuse and Mental Health Services Administration Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on Substance Abuse Treatment Facilities, DASIS Series: S-44. Rockville, MD; 2008. Report No.: DHHS Publication No. (SMA) 08-4348. Substance Abuse and Mental Health Services Administration Office of Applied Studies. National Survey of Substance Abuse Treatment Services (N-SSATS): 2007. Data on Substance Abuse Treatment Facilities, DASIS Series: S-44. Rockville, MD; 2008. Report No.: DHHS Publication No. (SMA) 08-4348.
21.
go back to reference Fiellin DA. The first three years of buprenorphine in the united states: experience to date and future directions. Journal of Addiction Medicine. 2007;1(2):62–7.CrossRef Fiellin DA. The first three years of buprenorphine in the united states: experience to date and future directions. Journal of Addiction Medicine. 2007;1(2):62–7.CrossRef
22.
go back to reference Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–51.CrossRefPubMed Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2009;36(3):244–51.CrossRefPubMed
23.
go back to reference Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–40.PubMed Cunningham CO, Sohler NL, McCoy K, Kunins HV. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med. 2006;38(5):336–40.PubMed
24.
go back to reference Elliott V. Links between primary care, addiction services may help treatment. American Medical News (amednews.com). 1-29-0001. Elliott V. Links between primary care, addiction services may help treatment. American Medical News (amednews.com). 1-29-0001.
25.
go back to reference Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286(14):1724–31.CrossRefPubMed Fiellin DA, O’Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA. 2001;286(14):1724–31.CrossRefPubMed
26.
go back to reference Fiellin DA, Barthwell A. Guideline development for office-based pharmacotherapies for opioid dependence. J Addict Dis. 2003;22:109–20.CrossRefPubMed Fiellin DA, Barthwell A. Guideline development for office-based pharmacotherapies for opioid dependence. J Addict Dis. 2003;22:109–20.CrossRefPubMed
27.
go back to reference Godden T, Byrne A, Wanigaratne S, Feinmann C. Care and shared care of opiate misusers by general practitioners in inner London. J Subst Misuse Nursing, Health Social Care. 1997;2(4):217–21. Godden T, Byrne A, Wanigaratne S, Feinmann C. Care and shared care of opiate misusers by general practitioners in inner London. J Subst Misuse Nursing, Health Social Care. 1997;2(4):217–21.
28.
go back to reference Sullivan L, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abuse. 2006;27(3):11–6. Sullivan L, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abuse. 2006;27(3):11–6.
29.
go back to reference Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41(6):891–6.CrossRefPubMed Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis. 2005;41(6):891–6.CrossRefPubMed
30.
go back to reference Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.CrossRefPubMed Turner BJ, Laine C, Lin YT, Lynch K. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med. 2005;165(15):1769–76.CrossRefPubMed
31.
go back to reference West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(Suppl 1):8–16.CrossRef West JC, Kosten TR, Wilk J, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. Am J Addict. 2004;13(Suppl 1):8–16.CrossRef
32.
go back to reference Green ML. Identifying, appraising, and implementing medical education curricula: a guide for medical educators. Ann Intern Med. 2001;135(10):889–96.PubMed Green ML. Identifying, appraising, and implementing medical education curricula: a guide for medical educators. Ann Intern Med. 2001;135(10):889–96.PubMed
33.
go back to reference Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus. 2006;27(3):39–45.CrossRefPubMed Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus. 2006;27(3):39–45.CrossRefPubMed
34.
go back to reference Wong JG, Holmboe ES, Jara GB, Martin J, Becker WC, Fiellin DA. Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence. Subst Abuse. 2004;25(4):35–40. Wong JG, Holmboe ES, Jara GB, Martin J, Becker WC, Fiellin DA. Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence. Subst Abuse. 2004;25(4):35–40.
36.
go back to reference Mills J, Lennon D, Francis K. Contributing to a culture of learning: a mentor development and support project for Australian rural nurses. Int J Nurs Pract. 2007;13(6):393–6.CrossRefPubMed Mills J, Lennon D, Francis K. Contributing to a culture of learning: a mentor development and support project for Australian rural nurses. Int J Nurs Pract. 2007;13(6):393–6.CrossRefPubMed
37.
go back to reference Hampson JP, Roberts RI, Morgan DA. Shared care: a review of the literature. Fam Pract. 1996;13(3):264–79.CrossRefPubMed Hampson JP, Roberts RI, Morgan DA. Shared care: a review of the literature. Fam Pract. 1996;13(3):264–79.CrossRefPubMed
38.
go back to reference Smith E, Mistral W. Shared care: lessons from one model of shared care nursing in primary care. Drugs: Education, Prevention & Policy. 2003;10(3):263–70.CrossRef Smith E, Mistral W. Shared care: lessons from one model of shared care nursing in primary care. Drugs: Education, Prevention & Policy. 2003;10(3):263–70.CrossRef
39.
go back to reference Liljestrand P, Goldschmidt RH. National HIV telephone consultation line [comment]. J Gen Intern Med. 1998;2(13):146. Liljestrand P, Goldschmidt RH. National HIV telephone consultation line [comment]. J Gen Intern Med. 1998;2(13):146.
Metadata
Title
The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment
Authors
James E. Egan, MPH
Paul Casadonte, MD
Tracy Gartenmann
Judith Martin, MD
Elinore F. McCance-Katz, MD, PhD
Julie Netherland, MSW
John A. Renner, MD
Linda Weiss, PhD
Andrew J. Saxon, MD
David A. Fiellin, MD
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue 9/2010
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-010-1377-y

Other articles of this Issue 9/2010

Journal of General Internal Medicine 9/2010 Go to the issue

Clinical Practice: Clinical Images

An Uncommon Cause of Headache

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine